[
  {
    "ts": null,
    "headline": "Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study",
    "summary": "Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentially pique investor interest. Despite this development, Amgen's stock saw a 2.42% decline last week, subtly countering the broader market movements where indices like the S&P 500 and Nasdaq reached all-time highs. The company's recent collaborations and forward-looking statements provide a context of optimism and...",
    "url": "https://finnhub.io/api/news?id=fa65059589b096caf76ec113b659989b2456edfbb90a80fb43fdcba83658b365",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757529609,
      "headline": "Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study",
      "id": 136689290,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentially pique investor interest. Despite this development, Amgen's stock saw a 2.42% decline last week, subtly countering the broader market movements where indices like the S&P 500 and Nasdaq reached all-time highs. The company's recent collaborations and forward-looking statements provide a context of optimism and...",
      "url": "https://finnhub.io/api/news?id=fa65059589b096caf76ec113b659989b2456edfbb90a80fb43fdcba83658b365"
    }
  },
  {
    "ts": null,
    "headline": "Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care",
    "summary": "Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, is kicking off its month of \"World Sight Day\" activities in alignment with the International Agency for the Prevention of Blindness (IAPB), the global champion for the observance, leading up to the worldwide day of awareness on Oct. 9, 2025.",
    "url": "https://finnhub.io/api/news?id=19d40b39f9ce8641fe2f2f279f32b558a95d23b48aa63aba2825220fda5e75b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757517300,
      "headline": "Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care",
      "id": 136689291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, is kicking off its month of \"World Sight Day\" activities in alignment with the International Agency for the Prevention of Blindness (IAPB), the global champion for the observance, leading up to the worldwide day of awareness on Oct. 9, 2025.",
      "url": "https://finnhub.io/api/news?id=19d40b39f9ce8641fe2f2f279f32b558a95d23b48aa63aba2825220fda5e75b8"
    }
  },
  {
    "ts": null,
    "headline": "Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership",
    "summary": "Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug conjugate.",
    "url": "https://finnhub.io/api/news?id=33be676d416451db2dc19eb1bb13dc839db67235f49e989e18f331ae23aea73a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757507580,
      "headline": "Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership",
      "id": 136688957,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug conjugate.",
      "url": "https://finnhub.io/api/news?id=33be676d416451db2dc19eb1bb13dc839db67235f49e989e18f331ae23aea73a"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Amgen (AMGN) Could Change Following Phase 3 Rocatinlimab Data Release",
    "summary": "Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy rocatinlimab in approximately 2,600 adults and adolescents with moderate to severe atopic dermatitis, as part of the global Phase 3 ROCKET clinical program. This clinical update highlights ongoing efforts to advance T-cell-targeted treatments for atopic dermatitis, an area with significant unmet patient needs. We'll examine how the ASCEND trial results for rocatinlimab...",
    "url": "https://finnhub.io/api/news?id=6585989048bf0c8ded61f0b1e7ffd41adcac860adfbcadcfe523ef3c278c0b07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757506439,
      "headline": "The Bull Case For Amgen (AMGN) Could Change Following Phase 3 Rocatinlimab Data Release",
      "id": 136689293,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy rocatinlimab in approximately 2,600 adults and adolescents with moderate to severe atopic dermatitis, as part of the global Phase 3 ROCKET clinical program. This clinical update highlights ongoing efforts to advance T-cell-targeted treatments for atopic dermatitis, an area with significant unmet patient needs. We'll examine how the ASCEND trial results for rocatinlimab...",
      "url": "https://finnhub.io/api/news?id=6585989048bf0c8ded61f0b1e7ffd41adcac860adfbcadcfe523ef3c278c0b07"
    }
  }
]